From the Department of Nuclear Medicine and Nancyclotep Imaging Platform.
Department of Hematology, Université de Lorraine, CHRU Nancy.
Clin Nucl Med. 2022 Feb 1;47(2):e152-e153. doi: 10.1097/RLU.0000000000003870.
18F-FDG PET/CT imaging series were acquired on a 64-year-old woman with refractory diffuse large B lymphoma to monitor chimeric antigen receptor (CAR) T-cell therapy. Because of a clinical deterioration, 18F-FDG PET/CT performed 8 days after CAR T-cell therapy suggested an early flare-up phenomenon with new lymph node involvement, lymph node progression while a decrease in metabolic tumor volume. The 18F-FDG PET/CT 1 month after CAR T-cell therapy confirmed this hypothesis. Pseudoprogression in solid tumors treated by immunotherapy has generally been reported later after treatment.
我们对一名难治性弥漫性大 B 细胞淋巴瘤老年女性患者进行了 18F-FDG PET/CT 系列检查，以监测嵌合抗原受体（CAR）T 细胞治疗效果。由于病情恶化，CAR T 细胞治疗后 8 天进行的 18F-FDG PET/CT 检查提示出现早期爆发现象，伴有新的淋巴结受累、淋巴结进展，同时代谢肿瘤体积减少。CAR T 细胞治疗 1 个月后的 18F-FDG PET/CT 检查结果证实了这一假说。免疫治疗治疗后的实体瘤假性进展通常在治疗后较晚出现。
